165 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Characterising side population genes in placentas from patients with preeclampsia and/or fetal growth restriction.
3. The Brain Natriuretic Peptide (BNP) system is expressed in the placenta and vasculature in preeclampsia: potential implications for novel therapeutic strategies
4. Upregulation of placental Ski-like proto-oncogene in preterm preeclampsia: potential target for preeclampsia treatment?
5. Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
6. Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?
7. Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia
8. Cell surface associated protein mucin 15 (MUC15) is elevated in preeclampsia
9. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity
10. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity
11. Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth
12. Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia
13. Circulating chemerin is elevated in women with preeclampsia
14. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model
15. Repurposing existing drugs as a therapeutic approach for the prevention of preterm birth
16. Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors
17. Endothelial protein C receptor is increased in preterm preeclampsia and fetal growth restriction
18. The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
19. Placental galectin-3 is reduced in early-onset preeclampsia
20. Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development
21. Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction
22. Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
23. Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
24. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
25. Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia
26. Transcriptional profiles of genes related to mitochondrial aging in placental pathologies
27. Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies
28. PSG7 and 9 (Pregnancy‐Specific β‐1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia
29. Circulating Activin A is elevated at 36 weeks’ gestation preceding a diagnosis of preeclampsia
30. Use of Metformin to Prolong Gestation in Preterm Pre-eclampsia: Randomised, Double Blind, Placebo Controlled Trial
31. Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction
32. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia
33. Clinical tools and biomarkers to predict preeclampsia
34. A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks’ gestation in pregnancies destined to deliver small for gestational age infants
35. NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast
36. Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling
37. Circulating trace elements for the prediction of preeclampsia and small for gestational age babies
38. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial
39. Prasugrel reduces hypertension and vascular constriction in human and animal models of preeclampsia
40. LOX-1 expression is reduced in placenta from cases of preeclampsia and in hypoxic cytotrophoblasts
41. P-065. New human models of preeclampsia; offering physiologically relevant assays for the development of therapeutics to ameliorate preeclamptic vascular dysfunction
42. Analysis of mitochondrial regulatory transcripts in publicly available datasets with validation in placentae from pre-term, post-term and fetal growth restriction pregnancies
43. O-004. Circulating SIGLEC6 is deranged in preeclampsia and may be a biomarker of disease severity
44. PSG9 – a novel biomarker deranged in preeclampsia
45. P-009. Associations between circulating sFlt-1 and PlGF and preeclampsia with severe maternal complications, or eclampsia
46. Elevated circulating and placental SPINT2 is associated with placental insufficiency
47. Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker
48. Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria
49. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
50. Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.